Immunomodulatory effect of bovine lactoferrin during SARS-CoV-2 infection

Front Immunol. 2024 Oct 17:15:1456634. doi: 10.3389/fimmu.2024.1456634. eCollection 2024.

Abstract

Introduction: Lactoferrin (Lf) is an important immunomodulator in infections caused by different agents. During SARS-CoV-2 infection, Lf can hinder or prevent virus access to the intracellular environment. Severe cases of COVID-19 are related to increased production of cytokines, accompanied by a weak type 1 interferon response.

Methods: We investigated the influence of bovine Lf (bLf) in the immune response during SARS-CoV-2 infection in vitro and in vivo assays.

Results: Our results show a strong binding between bLf and TLR4/NF-κB in silico, as well as an increase in mRNA expression of these genes in peripheral blood mononuclear cells (PBMCs) treated with bLf. Furthermore, the treatment increased TLR4/TLR9 mRNA expression in infected K18-hACE2 mouse blood, indicating an activation of innate response. Our results show that, when bLf was added, a reduction in the NK cell population was found, presenting a similar effect on PD-1 in TCD4+ and TCD8+ cells. In the culture supernatant of PBMCs from healthy participants, bLf decreased IL-6 levels and increased CCL5 in COVID-19 participants. In addition, K18-hACE2 mice infected and treated with bLf presented an increase of serum pro-inflammatory markers (GM-CSF/IL-1β/IL-2) and upregulated mRNA expression of IL1B and IL6 in the lung tissue. Furthermore, bLf treatment was able to restore FTH1 levels in brain tissue.

Discussion: The data indicate that bLf can be part of a therapeutic strategy to promote the immunomodulation effect, leading to homeostasis during COVID-19.

Keywords: COVID-19; TLR4; bovine lactoferrin; cytokines; immunomodulation.

MeSH terms

  • Adult
  • Animals
  • COVID-19 Drug Treatment
  • COVID-19* / immunology
  • COVID-19* / virology
  • Cattle
  • Cytokines / metabolism
  • Female
  • Humans
  • Immunologic Factors / pharmacology
  • Immunologic Factors / therapeutic use
  • Immunomodulating Agents / pharmacology
  • Immunomodulating Agents / therapeutic use
  • Killer Cells, Natural / drug effects
  • Killer Cells, Natural / immunology
  • Lactoferrin* / pharmacology
  • Lactoferrin* / therapeutic use
  • Leukocytes, Mononuclear* / drug effects
  • Leukocytes, Mononuclear* / immunology
  • Leukocytes, Mononuclear* / metabolism
  • Male
  • Mice
  • NF-kappa B / metabolism
  • SARS-CoV-2* / immunology
  • Toll-Like Receptor 4 / metabolism

Substances

  • Lactoferrin
  • Cytokines
  • Toll-Like Receptor 4
  • Immunologic Factors
  • NF-kappa B
  • Immunomodulating Agents

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study received financial support from Fundação Oswaldo Cruz (VPPCB‐005‐FIO‐20‐2‐11) to AAB, Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ E-26/211.369/2019, E-26/204.212/2022, E-26/200.205/2023) to JM and Ação Orçamentária 21C0 de Enfrentamento da Emergência de Saúde Pública de Importância Internacional Decorrente do Coronavírus from UNIRIO/Ministério da Educação do Governo do Brasil to RG. FAPERJ (E-26/201.098/2023, granted the Ryan Nascimento e Juliana Gil Melgaço.